Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Timothy M. Nywening

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5084371532. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 7

  1. Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-16245-1↗
  2. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1467↗
  3. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Co-author DOI 10.1038/s41467-018-03600-6↗
  4. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic du… Co-author DOI 10.1136/gutjnl-2017-313738↗
  5. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/s1470-2045(16)00078-4↗
  6. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Co-author DOI 10.18632/oncotarget.9551↗
  7. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Co-author DOI 10.1158/0008-5472.can-13-3723↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. William G. Hawkins · 5 shared papers, 2016–2024 · strength 0.42
  2. Ryan C Fields · 4 shared papers, 2016–2024 · strength 0.37
  3. David C. Linehan · 5 shared papers, 2014–2020 · strength 0.31
  4. David G DeNardo · 5 shared papers, 2014–2018 · strength 0.27
  5. Roheena Z. Panni · 4 shared papers, 2016–2020 · strength 0.27
  6. Adetunji T. Toriola · 2 shared papers, 2016–2024 · strength 0.23
  7. Joshua D. Mitchell · 1 shared paper, 2024 · strength 0.19
  8. Linda R. Peterson · 1 shared paper, 2024 · strength 0.19
  9. Usman Younis Panni · 1 shared paper, 2024 · strength 0.19
  10. Joseph E. Ippolito · 1 shared paper, 2024 · strength 0.19
  11. Dominic E. Sanford · 2 shared papers, 2016–2018 · strength 0.11
  12. Melissa A. Meyer · 2 shared papers, 2014–2018 · strength 0.11
  13. Ryan R. Kawalerski · 1 shared paper, 2020 · strength 0.09
  14. Naim U. Rashid · 1 shared paper, 2020 · strength 0.09
  15. Richard A. Moffitt · 1 shared paper, 2020 · strength 0.09
  16. Jen Jen Yeh · 1 shared paper, 2020 · strength 0.09
  17. Andrea Wang‐Gillam · 2 shared papers, 2014–2016 · strength 0.09
  18. John M. Baer · 1 shared paper, 2018 · strength 0.07
  19. Cynthia X Ma · 1 shared paper, 2018 · strength 0.07
  20. Booyeon Julia Han · 1 shared paper, 2018 · strength 0.07
  21. Peter S. Goedegebuure · 1 shared paper, 2018 · strength 0.07
  22. William E. Gillanders · 1 shared paper, 2018 · strength 0.07
  23. Dirk M. Spitzer · 1 shared paper, 2016 · strength 0.05
  24. Kerri A. Ohman · 1 shared paper, 2016 · strength 0.05
  25. Yassar M. Hashim · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.